Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736990 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Calluna Pharma AS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06736990: Recruiting Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Calluna Pharma AS.
NCT06736990 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Calluna Pharma AS. The registered enrollment target is 150 participants, below the 749-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736990, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Calluna Pharma AS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CAL101
Study Locations (20)
Other
- Aarhus University Hospital - Aarhus
- Rigshospitalet - Copenhagen
- Odense University Hospital - Odense
- AP-HP Hopital Avicenne - Bobigny
- AP-HP Hopital Europeen Georges Pompidou - Paris
- CHU Rennes - Hopital Pontchaillou - Rennes
- CHU de Toulouse - Hopital Larrey - Toulouse
- CHRU de Tours - Hôpital Bretonneau - Tours
North Carolina
- Pulmonix, LLC - Greensboro
- Southeastern Research Center - Winston-Salem
California
- Keck School of Medicine at USC - Los Angeles
Colorado
- National Jewish Health - Denver
Florida
- Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research - Miami
Kansas
- University of Kansas Medical Center - Kansas City
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Temple University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT06736990 shows while recruiting
NCT06736990 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 749-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06736990 names 20 study sites across 12 states, led by Other, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT06736990 about?
NCT06736990 is a clinical study titled "A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis". The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants w...
What is the current status of trial NCT06736990?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-06-20. Estimated completion is 2027-11.
What conditions does trial NCT06736990 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT06736990?
The interventions under investigation include: Placebo (DRUG), CAL101 (DRUG).
Who is sponsoring clinical trial NCT06736990?
This trial is sponsored by Calluna Pharma AS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736990 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Kansas, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06736990's enrollment target sits among peer trials
150 19th of 51 higher than 33 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI